King Pharmaceuticals Research and Development, Inc.
Records under this name other than patents King Pharmaceuticals Research and Development, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to King Pharmaceuticals Research and Development, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,714,006 | Methods of modifying the bioavailability of metaxalone Term ended Term ended Jan 14, 2025 · USPTO record | Term ended | Term ended Jan 14, 2025 | USPTO record |
| US 7,005,416 | Dalfopristine/Quinupristine Combinations with Cefpirome Term ended Term ended Aug 10, 2022 · High confidence | Term ended | Term ended Aug 10, 2022 | High confidence |
| US 6,555,581 | Levothyroxine compositions and methods Term ended Term ended Feb 15, 2022 · USPTO record | Term ended | Term ended Feb 15, 2022 | USPTO record |
| US 7,067,148 | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation Term ended Term ended Feb 15, 2022 · USPTO record | Term ended | Term ended Feb 15, 2022 | USPTO record |
| US 6,407,128 | Method for increasing the bioavailability of metaxalone Term ended Term ended Dec 3, 2021 · USPTO record | Term ended | Term ended Dec 3, 2021 | USPTO record |
| US 6,683,102 | Methods of using metaxalone in the treatment of musculoskeletal conditions Term ended Term ended Dec 3, 2021 · USPTO record | Term ended | Term ended Dec 3, 2021 | USPTO record |
| US 6,248,774 | Method for treating hyper-excited sensory nerve functions in humans Term ended Term ended Sep 5, 2020 · USPTO record | Term ended | Term ended Sep 5, 2020 | USPTO record |
| US 6,187,746 | Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof Term ended Term ended Dec 15, 2018 · USPTO record | Term ended | Term ended Dec 15, 2018 | USPTO record |
| US 7,271,171 | Adenosine A3 receptor modulators Term ended Term ended Oct 1, 2018 · USPTO record | Term ended | Term ended Oct 1, 2018 | USPTO record |
| US 6,407,236 | Adenosine A3 receptor modulators Term ended Term ended Sep 16, 2018 · USPTO record | Term ended | Term ended Sep 16, 2018 | USPTO record |